The classification of cyclooxygenase inhibitors

P. E. Lipsky, S. B. Abramson, L. Crofford, R. N. Dubois, L. S. Simon, L. B.A. Van de Putte

    Research output: Contribution to journalEditorialpeer-review

    113 Scopus citations

    Abstract

    In summary, precise classification of COX inhibitors has important clinical implications for efficacy and toxicity. However, classification of these agents clinically is difficult because there are insufficient data to predict correlations between biochemical and pharmacologic properties and the clinical effect of a given agent. In any case, specific COX-2 inhibitors are expected to show antiinflammatory and analgesic activities equivalent to those of NSAID, as well as significant reductions in the incidence of the life threatening side effects (i.e., GI bleeding) associated with COX-1 inhibition. The advantages of preferential COX-2 inhibitors may be more subtle and therefore more difficult to verify in clinical trials.

    Original languageEnglish (US)
    Pages (from-to)2298-2303
    Number of pages6
    JournalJournal of Rheumatology
    Volume25
    Issue number12
    StatePublished - Dec 15 1998

    ASJC Scopus subject areas

    • Rheumatology
    • Immunology and Allergy
    • Immunology

    Fingerprint Dive into the research topics of 'The classification of cyclooxygenase inhibitors'. Together they form a unique fingerprint.

    Cite this